Canada markets closed

Emmaus Life Sciences, Inc. (EMMA)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1050-0.0120 (-10.26%)
At close: 12:42PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.1170
Open0.1290
Bid0.0000 x 1800
Ask0.0000 x 1300
Day's Range0.1050 - 0.1290
52 Week Range0.0510 - 0.3540
Volume5,333
Avg. Volume19,595
Market Cap5.632M
Beta (5Y Monthly)1.72
PE Ratio (TTM)N/A
EPS (TTM)-0.0800
Earnings DateMar 29, 2024 - Apr 12, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico

    Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease (SCD) treatment, today announced that it has received marketing authorization from the Puerto Rico Department of Health for Endari® (L-glutamine oral powder). This approval marks a significant milestone in Emmaus' mission to improve the lives of people with SCD around the world and provides access to this important therapy for the patients living with SCD in Puerto Rico. In addition, Endari® is approved in the United State

  • PR Newswire

    Emmaus Life Sciences Reports Q3 2023 Financial Results

    Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2023.